Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report

View ORCID ProfileShiv Gandhi, Jonathan Klein, Alexander Robertson, Mario A. Peña-Hernández, Michelle J Lin, View ORCID ProfilePavitra Roychoudhury, Peiwen Lu, John Fournier, David Ferguson, Shah A. Mohamed Bakhash, M. Catherine Muenker, Ariktha Srivathsan, Elsio A. Wunder Jr, Nicholas Kerantzas, Wenshuai Wang, Anna Pyle, Craig B. Wilen, Onyema Ogbuagu, View ORCID ProfileAlexander L. Greninger, View ORCID ProfileAkiko Iwasaki, View ORCID ProfileWade L. Schulz, View ORCID ProfileAlbert I. Ko
doi: https://doi.org/10.1101/2021.11.08.21266069
Shiv Gandhi
1Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shiv Gandhi
  • For correspondence: shiv.gandhi@yale.edu albert.ko@yale.edu
Jonathan Klein
2Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Robertson
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario A. Peña-Hernández
2Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle J Lin
4Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pavitra Roychoudhury
4Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pavitra Roychoudhury
Peiwen Lu
2Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Fournier
1Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Ferguson
5Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shah A. Mohamed Bakhash
4Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Catherine Muenker
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ariktha Srivathsan
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elsio A. Wunder Jr
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Kerantzas
6Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenshuai Wang
7Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Pyle
7Department of Molecular, Cellular and Developmental Biology, Yale University, New Haven, CT, USA
8Department of Chemistry, Yale University, New Haven, CT, USA
10Howard Hughes Medical Institute, Chevy Chase, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig B. Wilen
2Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
6Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Onyema Ogbuagu
1Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander L. Greninger
4Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington, USA
9Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexander L. Greninger
Akiko Iwasaki
2Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
6Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA
10Howard Hughes Medical Institute, Chevy Chase, MD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Akiko Iwasaki
Wade L. Schulz
5Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA
6Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wade L. Schulz
Albert I. Ko
1Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA
3Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Albert I. Ko
  • For correspondence: shiv.gandhi@yale.edu albert.ko@yale.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

SARS-CoV-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. We present a case of an immunocompromised patient with acquired B-cell deficiency who developed an indolent, protracted course of SARS-CoV-2 infection. Remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. Whole genome sequencing identified a mutation, E802D, in the nsp12 RNA-dependent RNA polymerase which was not present in pre-treatment specimens. In vitro experiments demonstrated that the mutation conferred a ∼6-fold increase in remdesivir IC50 but resulted in a fitness cost in the absence of remdesivir. Sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. Although the fitness cost observed in vitro may limit the risk posed by E802D, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with SARS-CoV-2 infection.

Competing Interest Statement

ALG reports institutional central testing contracts from Abbott and research grants from Merck and Gilead, outside of the proposed work. AIK received consulting fees from Tata Sons and is recipient of grants on COVID-19 from Merck, Regeneron and Serimmune all of which are outside the submitted work. OO received consulting fees from Gilead and ViiV, as well as research support and honoraria from Gilead, outside of the submitted work. WLS is a consultant for Hugo Health, founder of Refactor Health and is recipient of grants on COVID-19 from Merck and Regeneron, all of which are outside the submitted work.

Funding Statement

This study was supported by the Beatrice Kleinberg Neuwirth Fund; the Sendas Family Fund, Yale School of Public Health; and Department of Internal Medicine at the Yale School of Medicine. SG was supported by a grant from the National Institutes of Health (2T32AI007517-21A1). C.B.W. was supported by Burroughs Welcome Fund, Ludwig Family Foundation, and Mathers Foundation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was also approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, protocol ID 2000027690, 2000029277). Informed consent was obtained from both the patient and healthcare workers.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Sequencing data are available under NCBI BioProject no. PRJNA774781

https://www.ncbi.nlm.nih.gov/bioproject/?term=774781

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted November 09, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report
Shiv Gandhi, Jonathan Klein, Alexander Robertson, Mario A. Peña-Hernández, Michelle J Lin, Pavitra Roychoudhury, Peiwen Lu, John Fournier, David Ferguson, Shah A. Mohamed Bakhash, M. Catherine Muenker, Ariktha Srivathsan, Elsio A. Wunder Jr, Nicholas Kerantzas, Wenshuai Wang, Anna Pyle, Craig B. Wilen, Onyema Ogbuagu, Alexander L. Greninger, Akiko Iwasaki, Wade L. Schulz, Albert I. Ko
medRxiv 2021.11.08.21266069; doi: https://doi.org/10.1101/2021.11.08.21266069
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: A case report
Shiv Gandhi, Jonathan Klein, Alexander Robertson, Mario A. Peña-Hernández, Michelle J Lin, Pavitra Roychoudhury, Peiwen Lu, John Fournier, David Ferguson, Shah A. Mohamed Bakhash, M. Catherine Muenker, Ariktha Srivathsan, Elsio A. Wunder Jr, Nicholas Kerantzas, Wenshuai Wang, Anna Pyle, Craig B. Wilen, Onyema Ogbuagu, Alexander L. Greninger, Akiko Iwasaki, Wade L. Schulz, Albert I. Ko
medRxiv 2021.11.08.21266069; doi: https://doi.org/10.1101/2021.11.08.21266069

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (501)
  • Anesthesia (110)
  • Cardiovascular Medicine (1233)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (529)
  • Epidemiology (10012)
  • Forensic Medicine (5)
  • Gastroenterology (498)
  • Genetic and Genomic Medicine (2448)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1636)
  • Health Policy (751)
  • Health Systems and Quality Improvement (635)
  • Hematology (248)
  • HIV/AIDS (532)
  • Infectious Diseases (except HIV/AIDS) (11860)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2277)
  • Nursing (139)
  • Nutrition (350)
  • Obstetrics and Gynecology (452)
  • Occupational and Environmental Health (534)
  • Oncology (1245)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (155)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (729)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4828)
  • Radiology and Imaging (834)
  • Rehabilitation Medicine and Physical Therapy (490)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (226)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)